OBJECTIVE: To estimate trends in contraceptive use, especially long-acting reversible contraceptives (LARCs) and condoms, among human immunodeficiency virus (HIV)-seropositive and HIV-seronegative women. METHODS: Human immunodeficiency virus-seropositive and HIV-seronegative women in a multicenter longitudinal cohort were interviewed semiannually between 1998 and 2010 about sexual behaviors and contraceptive use. Trends in contraceptive use by women aged 18-45 years who were at risk for unintended pregnancy but not trying to conceive were analyzed using generalized estimating equations. RESULTS: Condoms were the dominant form of contraception for HIV-seropositive women and showed little change across time. Less than 15% of these women used no contraception. Between 1998 and 2010, LARC use increased among HIV-seronegative women from 4.8% (6 of 126) to 13.5% (19 of 141, P=.02), but not significantly among seropositive women (0.9% [4 of 438] to 2.8% [6 of 213], P=.09). Use of highly effective contraceptives, including pills, patches, rings, injectable progestin, implants, and intrauterine devices, ranged from 15.2% (53 of 348) in 1998 to 17.4% (37 of 213) in 2010 (P=.55). Human immunodeficiency virus-seronegative but not HIV-seropositive LARC users were less likely than nonusers to use condoms consistently (hazard ratio 0.51, 95% confidence interval [CI] 0.32-0.81, P=.004 for seronegative women; hazard ratio 1.09, 95% CI 0.96-1.23 for seropositive women). CONCLUSION: Although most HIV-seropositive women use contraception, they rely primarily on condoms and have not experienced the increase in LARC use seen among seronegative women. Strategies to improve simultaneous use of condoms and LARC are needed to minimize risk of unintended pregnancy as well as HIV transmission and acquisition of sexually transmitted infections. LEVEL OF EVIDENCE: II.
OBJECTIVE: To estimate trends in contraceptive use, especially long-acting reversible contraceptives (LARCs) and condoms, among humanimmunodeficiency virus (HIV)-seropositive and HIV-seronegative women. METHODS:Human immunodeficiency virus-seropositive and HIV-seronegative women in a multicenter longitudinal cohort were interviewed semiannually between 1998 and 2010 about sexual behaviors and contraceptive use. Trends in contraceptive use by women aged 18-45 years who were at risk for unintended pregnancy but not trying to conceive were analyzed using generalized estimating equations. RESULTS: Condoms were the dominant form of contraception for HIV-seropositive women and showed little change across time. Less than 15% of these women used no contraception. Between 1998 and 2010, LARC use increased among HIV-seronegative women from 4.8% (6 of 126) to 13.5% (19 of 141, P=.02), but not significantly among seropositive women (0.9% [4 of 438] to 2.8% [6 of 213], P=.09). Use of highly effective contraceptives, including pills, patches, rings, injectable progestin, implants, and intrauterine devices, ranged from 15.2% (53 of 348) in 1998 to 17.4% (37 of 213) in 2010 (P=.55). Human immunodeficiency virus-seronegative but not HIV-seropositive LARC users were less likely than nonusers to use condoms consistently (hazard ratio 0.51, 95% confidence interval [CI] 0.32-0.81, P=.004 for seronegative women; hazard ratio 1.09, 95% CI 0.96-1.23 for seropositive women). CONCLUSION: Although most HIV-seropositive women use contraception, they rely primarily on condoms and have not experienced the increase in LARC use seen among seronegative women. Strategies to improve simultaneous use of condoms and LARC are needed to minimize risk of unintended pregnancy as well as HIV transmission and acquisition of sexually transmitted infections. LEVEL OF EVIDENCE: II.
Authors: S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman Journal: Epidemiology Date: 1998-03 Impact factor: 4.822
Authors: L Stewart Massad; Gayle Springer; Lisa Jacobson; Heather Watts; Kathryn Anastos; Abner Korn; Helen Cejtin; Alice Stek; Mary Young; Julie Schmidt; Howard Minkoff Journal: AIDS Date: 2004-01-23 Impact factor: 4.177
Authors: Jessica L Castilho; Cathy A Jenkins; Bryan E Shepherd; Sally S Bebawy; Megan Turner; Timothy R Sterling; Vlada V Melekhin Journal: J Womens Health (Larchmt) Date: 2015-03-09 Impact factor: 2.681
Authors: Rena Patel; Sarah Baum; Daniel Grossman; Rachel Steinfeld; Maricianah Onono; Craig Cohen; Elizabeth Bukusi; Sara Newmann Journal: AIDS Patient Care STDS Date: 2014-06-13 Impact factor: 5.078
Authors: Lisa B Haddad; Kristin M Wall; C Christina Mehta; Elizabeth T Golub; Lisa Rahangdale; Mirjam-Colette Kempf; Roksana Karim; Rodney Wright; Howard Minkoff; Mardge Cohen; Seble Kassaye; Deborah Cohan; Igho Ofotokun; Susan E Cohn Journal: Am J Obstet Gynecol Date: 2016-09-15 Impact factor: 8.661
Authors: Christine M Zachek; Lara E Coelho; Rosa M S M Domingues; Jesse L Clark; Raquel B De Boni; Paula M Luz; Ruth K Friedman; Ângela C Vasconcelos de Andrade; Valdilea G Veloso; Jordan E Lake; Beatriz Grinsztejn Journal: AIDS Behav Date: 2019-06
Authors: L Stewart Massad; Elizabeth M Daubert; Charlesnika T Evans; Howard Minkoff; Seble Kassaye; Jodie Dionne-Odom; Dominika Seidman; Kerry Murphy; Maria L Alcaide; Adaora A Adimora; Anandi N Sheth; Elizabeth T Golub; Audrey L French; Kathleen M Weber Journal: J Womens Health (Larchmt) Date: 2021-08-27 Impact factor: 3.017
Authors: Lisa B Haddad; Michael Monsour; Naomi K Tepper; Maura K Whiteman; Athena P Kourtis; Denise J Jamieson Journal: Am J Obstet Gynecol Date: 2017-09-01 Impact factor: 8.661
Authors: Anandi N Sheth; Christine D Angert; Lisa B Haddad; C Christina Mehta; Susan E Cohn Journal: Contraception Date: 2020-11-12 Impact factor: 3.375
Authors: Anna Hachfeld; Andrew Atkinson; Alexandra Calmy; Begoña Martinez de Tejada; Barbara Hasse; Paolo Paioni; Christian R Kahlert; Noémie Boillat-Blanco; Marcel Stoeckle; Karoline Aebi-Popp Journal: HIV Med Date: 2021-09-02 Impact factor: 3.094